Sort   by:  
 Page size 
UnknownDrug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures.
Not available
S-EPMC8507629 | biostudies-literature
UnknownPatient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer.
Not available
S-EPMC10790458 | biostudies-literature
UnknownDuration of Time Intervals for Risk Minimization Measure Effectiveness Studies.
Not available
S-EPMC11924164 | biostudies-literature
UnknownOvercoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes.
Not available
S-EPMC8771558 | biostudies-literature
UnknownMinimal clinically important improvement (MCII) and patient-acceptable symptom state (PASS) in total hip arthroplasty (THA) patients 1 year postoperatively.
Not available
S-EPMC3940990 | biostudies-literature
UnknownComparison design and evaluation power in cohort and self-controlled case series designs for post-authorization vaccine safety studies.
Not available
S-EPMC10812582 | biostudies-literature
ProteomicsSurprisal Analysis of Patient-Specific Signaling Networks in TNBC
The present study sought to combine surprisal analysis, utilizing systems-level data to predict unbalanced processes in each patient tumor, with quantitative analysis of tyrosine phosphorylation mediated signaling networks to identify potential therapeutic targets and therapeutic combinations in TNB...
ORGANISM(S): Homo sapiens (Human) 
2025-01-14 | PXD042640 | Pride
Surprisal analysis Pdx Triple negative breast cancer Phosphoproteomics Passs 
Sort   by:  
 Page size